SCHEMBL4423337

SCHEMBL4423337

Cc1cc(-c2ccc(C(=O)Nc3ccc4cccnc4c3)cc2)ccn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
MMP9 P14780 2/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
POLB P06746 1/20 0.59
TRPV1 Q8NER1 2/20 0.58
PABPC1 P11940 1/20 0.53
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
CYP2C19 P33261 1/20 0.51
KLK7 P49862 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4433847 0.87 MEN1 (0.73) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4428142 0.86 MEN1 (0.65) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4428905 0.86 TRPV1 (0.76) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4427491 0.83 MEN1 (0.67) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4435483 0.82 MEN1 (0.63) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4432764 0.82 MEN1 (0.65) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4436093 0.81 MEN1 (0.68) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL4435544 0.81 NPC1 (0.65) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL4425121 0.81 ATM (0.60) MEN1KMT2AMMP9NPC1RAB9A
SCHEMBL7101847 0.80 PABPC1 (0.79) MEN1KMT2ANPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 MEN1 3527/4885KMT2A 3992/4885MMP9 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.